Immunogenicity of bone morphogenetic proteins: A review

Journal of Neurosurgery: Spine

Volumn 10, Issue 5, 2009, Pages 443-451

  Hwang, Chang Ju ^a   Vaccaro, Alexander R ^a,d   Lawrence, James P ^a   Hong, Joseph ^a   Schellekens, Huub ^b   Alaoui Ismaili, Moulay Hicham ^c   Falb, Dean ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Stryker Orthopaedics   (United States)

^d ROTHMAN INSTITUTE   (United States)

Author keywords

Antibody formation; Bone morphogenetic protein; Immunogenicity; Osteogenic protein 1; Recombinant human BMP 2

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CARBOXYMETHYLCELLULOSE; COLLAGEN TYPE 1; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROTEIN ANTIBODY; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1;

ANTERIOR SPINE FUSION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; BIODEGRADABLE IMPLANT; BONE GRAFT; CLINICAL TRIAL; COMPOSITE GRAFT; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FRACTURE HEALING; HUMAN; IMMUNOGENICITY; INTERVERTEBRAL DISKECTOMY; NONHUMAN; OSTEOSYNTHESIS; REVIEW; SPINE FUSION;

ANTIBODY FORMATION; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; HUMANS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 66449136302     PISSN: 15475654     EISSN: 15475646     Source Type: Journal    
DOI: 10.3171/2009.1.SPINE08473     Document Type: Review

References (74)

1. Adair F, Ozanne D: The immunogenicity of therapeutic proteins. BioPharm International 15:30-36, 2002 (Pubitemid 34131989)
2. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA: A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 28:1219-1225, 2003 (Pubitemid 36734609)
3. Boden SD, Kang J, Sandhu H, Heller JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27:2662-2673, 2002 (Pubitemid 35425320)
4. Boden SD, Zdeblick TA, Sandhu HS, Heim SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 25:376-381, 2000 (Pubitemid 30097051)
5. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA: Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 15:337-349, 2002 (Pubitemid 35403089)
6. Burkus JK, Sandhu HS, Gornet MF, Longley MC: Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 87:1205-1212, 2005 (Pubitemid 40756620)
7. Canalis E, Economides AN, Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235, 2003 (Pubitemid 36515285)
8. Carreon LY, Glassman SD, Brock DC, Dimar JR, Puno RM, Campbell MJ: Adverse events in patients re-exposed to bone morphogenetic protein for spine surgery. Spine 33:391-393, 2008
9. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin- Dupont P, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002 (Pubitemid 34441737)
10. Chackerian B, Lenz P, Lowy DR, Schiller JT: Determinants of autoantibody induction by conjugated papillomavirus viruslike particles. J Immunol 169:6120-6126, 2002 (Pubitemid 36903455)
11. Charriere G, Bejot M, Schnitzler L, Ville G, Hartmann DJ: Reactions to a bovine collagen implant. Clinical and immunologic study in 705 patients. J Am Acad Dermatol 21:1203-1208, 1989 (Pubitemid 20216989)
12. Cornell CN, Lane JM, Chapman M, Merkow R, Seligson D, Henry S, et al: Multicenter trial of Collagraft as bone graft substitute. J Orthop Trauma 5:1-8, 1991
13. Damien CJ, Grob D, Boden SD, Benedict JJ: Purified bovine BMP extract and collagen for spine arthrodesis: preclinical safety and efficacy. Spine 27:S50-S58, 2002
14. De Groot AS, Scott DW: Immunogenicity of protein therapeutics. Trends Immunol 28:482-490, 2007 (Pubitemid 350087812)
15. Dietrich W, Späth P, Zühlsdorf M, Dalichau H, Kirchhoff PG, Kuppe H, et al: Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 95:64-71, 2001 (Pubitemid 32622998)
16. Elson Ml: The role of skin testing in the use of collagen injectable materials. J Dermatol Surg Oncol 15:301-303, 1989 (Pubitemid 19085790)
17. Erickson BP, Pierce AR, Simpson AK, Nash J, Grauer JN: 125I-labeled OP-1 is locally retained in a rabbit lumbar fusion model. Clin Orthop Relat Res 466:210-215, 2008
18. Committee for Proprietary Medicinal Products: European Public Assessment Report on Osteogenic Protein 1. European Agency for the Evaluation of Medicinal Products, 2001, London, England
19. Fernandes AI, Gregoriadis G: The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 217:215-224, 2001 (Pubitemid 32268647)
20. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, et al: Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235-1244, 1993 (Pubitemid 23219259)
21. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, et al: Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A (Suppl 1:S151-S158, 2001
22. Friess W, Uludag H, Foskett S, Biron R, Sargeant C: Characterization of absorbable collagen sponges as recombinant human bone morphogenetic protein-2 carriers. Int J Pharm 185:51-60, 1999 (Pubitemid 29333096)
23. Geesink RG, Hoefnagels NH, Bulstra SK: Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81:710-718, 1999
24. Geiger M, Li RH, Friess W: Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 55:1613-1629, 2003 (Pubitemid 37420006)
25. Gershon SK, Luksenburg H, Coté TR, Braun MM: Pure redcell aplasia and recombinant erythropoietin. N Engl J Med 346:1584-1586, 2002
26. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, et al: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123-2134, 2002 (Pubitemid 35417689)
27. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al: Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321:1-18, 2007 (Pubitemid 46454303)
28. Haid RW Jr, Branch CL Jr, Alexander JT, Burkus JK: Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 4:527-529, 2004 (Pubitemid 40029169)
29. Hansen SM, Sasso RC: Resorptive response of rhBMP2 simulating infection in an anterior lumbar interbody fusion with a femoral ring. J Spinal Disord Tech 19:130-134, 2006 (Pubitemid 44284159)
30. Harwood PJ, Giannoudis PV: Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects. Expert Opin Drug Saf 4:75-89, 2005
31. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W: Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903, 2004 (Pubitemid 38870136)
32. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, et al: Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88:1431-1441, 2006
33. Khan SN, Sandhu HS, Lane JM, Cammisa FP Jr, Girardi FP: Bone morphogenetic proteins: relevance in spine surgery. Orthop Clin North Am 33:447-463, ix, 2002 (Pubitemid 34701291)
34. Korchynskyi O, ten Dijke P: Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277:4883-4891, 2002 (Pubitemid 34968524)
35. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248, 2001
36. Louis-Ugbo J, Kim HS, Boden SD, Mayr MT, Li RC, Seeherman H, et al: Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 20:1050-1059, 2002
37. Lynn AK, Yannas IV, Bonfield W: Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater 71:343-354, 2004 (Pubitemid 39463770)
38. Martin GJ Jr, Boden SD, Marone MA, Moskovitz PA: Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 12:179-186, 1999 (Pubitemid 30263403)
39. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N: Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 19:483-486, 2006 (Pubitemid 44526745)
40. McGrath K, Patterson R: Immunology of streptokinase in human subjects. Clin Exp Immunol 62:421-426, 1985 (Pubitemid 16238006)
41. McKay B, Sandhu HS: Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 27:S66-S85, 2002
42. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1-16, 2004 (Pubitemid 38900899)
43. Muschler GF, Negami S, Hyodo A, Gaisser D, Easley K, Kambic H: Evaluation of collagen ceramic composite graft materials in a spinal fusion model. Clin Orthop Relat Res 328:250-260, 1996 (Pubitemid 26231151)
44. Nickel J, Dreyer MK, Kirsch T, Sebald W: The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg Am 83-A (Suppl 1:S7-S14, 2001 (Pubitemid 32246595)
45. Pendley C, Schantz A, Wagner C: Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172-179, 2003 (Pubitemid 36626459)
46. Pierce AR, Alaoui-Ismaili MH, Denison N, Schroeder R, Schrier D, Falb D: Teratology studies in NZW rabbits following immunization with bone morphogenetic protein-7 (BMP-7). Toxicol Sci 96:444, 2007 (unverified)
47. Pluhar GE, Turner AS, Pierce AR, Toth CA, Wheeler DL: A comparison of two biomaterial carriers for osteogenic protein-1 (BMP-7) in an ovine critical defect model. J Bone Joint Surg Br 88:960-966, 2006 (Pubitemid 44057189)
48. Porter S: Human immune response to recombinant human proteins. J Pharm Sci 90:1-11, 2001 (Pubitemid 32050471)
49. Poynton AR, Lane JM: Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 27:S40-S48, 2002
50. Pradhan BB, Bae HW, Dawson EG, Patel VV, Delamarter RB: Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine 31:E277-E284, 2006
51. Rosenberg AS: Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 112:15-21, 2003
52. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, et al: Immunogenicity of interferonbeta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48:706-712, 2000
53. Schellekens H: Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 18:1257-1259, 2003 (Pubitemid 36826943)
54. Schellekens H: Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720-1740, 2002 (Pubitemid 35440946)
55. Schellekens H, Ryff JC, van der Meide PH: Assays for antibodies to human interferon-alpha: the need for standardization. J Interferon Cytokine Res 17 (Suppl 1:S5-S8, 1997 (Pubitemid 27327277)
56. Schernthaner G: Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155-165, 1993 (Pubitemid 23348330)
57. Seeherman H, Wozney J, Li R: Bone morphogenetic protein delivery systems. Spine 27:S16-S23, 2002
58. Shankar G, Shores E, Wagner C, Mire-Sluis A: Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24:274-280, 2006 (Pubitemid 43853075)
59. Sharma B: Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv 25:310-317, 2007 (Pubitemid 46498672)
60. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, et al: Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31:542-547, 2006
61. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG: Increased swelling complications associated with off-label usage of rh-BMP-2 in the anterior cervical spine. Spine 31:2813-2819, 2006 (Pubitemid 44772783)
62. US Food and Drug Administration: Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs. Rockville, MD: US Food and Drug Administration, 2002 (http://www.fda.gov/Cder/Guidance/4945fnl.PDF) [Accessed 12 February 2009]
63. US Food and Drug Administration: Information on Premarket Approval Applications. INFUSE Bone Graft. Rockville, MD: US Food and Drug Administration, 2002 (http:// www.fda.gov/cdrh/pdf5/p050053.html) [Accessed 12 February 2009]
64. Vaccaro AR, Anderson DG, Toth CA: Recombinant human osteogenic protein-1 (bone morphogenetic protein-7) as an osteoinductive agent in spinal fusion. Spine 27:S59-S65, 2002
65. Vaccaro AR, Lawrence JP, Patel T, Katz LD, Anderson DG, Fischgrund JS, et al: The safety and efficacy of OP-1 (rhBMP- 7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis. Spine 33:2850-2862, 2008
66. Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F, et al: Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106:2263-2270, 2002 (Pubitemid 35222223)
67. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE: Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res 395:110-120, 2002 (Pubitemid 34136661)
68. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R: Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278:1-17, 2003 (Pubitemid 37281188)
69. Walker DH, Wright NM: Bone morphogenetic proteins and spinal fusion. Neurosurg Focus 13:E3, 2002
70. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD: Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 31:735-741, 2007 (Pubitemid 350160312)
71. Worobec A, Rosenberg AS: A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 1: Considering consequences of the immune response to a protein. BioPharm International 17:22-26, 2004 (Pubitemid 39573552)
72. Wozney JM: Overview of bone morphogenetic proteins. Spine 27:S2-S8, 2002
73. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al: Novel regulators of bone formation: molecular clones and activities. Science 242:1528-1534, 1988 (Pubitemid 19023695)
74. Zdeblick TA, Heim SE, Kleeman TJ: Laparoscopic approach with tapered metal cages: rhBMP-2 vs autograft. Read at the Annual Meeting of the North American Spine Society, Oct 31-Nov 3, 2001, Seattle, WA